ArticleScientific reports2016
Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Pooled it
- Cancer in disguise: a parasite within.The EMBO journal · 2026Review
- The differential role of IL-33 and IL-38 in prostate cancer, contradictory roles.Frontiers in immunology · 2025Review
- The effects of glycemic index on prostate cancer progression in a xenograft mouse model.Prostate cancer and prostatic diseases · 2024Article
- A diversity of novel type-2 innate lymphoid cell subpopulations revealed during tumour expansion.Communications biology · 2024Article
- A novel type-2 innate lymphoid cell-based immunotherapy for cancer.Frontiers in immunology · 2024Article
- A novel cell-based screen identifies chemical entities that reverse the immune-escape phenotype of metastatic tumours.Frontiers in pharmacology · 2023Article
- Curcuphenol possesses an unusual histone deacetylase enhancing activity that counters immune escape in metastatic tumours.Frontiers in pharmacology · 2023Article
- Interleukin-33 as a Potential Therapeutic Target in Gastric Cancer Patients: Current Insights.OncoTargets and therapy · 2023Review
- Insights into the tumor microenvironment of B cell lymphoma.Journal of experimental & clinical cancer research : CR · 2022Review
- Article
- Innate lymphoid cells in colorectal cancer.Scandinavian journal of immunology · 2022Review
- Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.Cancers · 2022Review
- Specific cannabinoids revive adaptive immunity by reversing immune evasion mechanisms in metastatic tumours.Frontiers in immunology · 2022Article
- Heterogeneity of ILC2s in the Lungs.Frontiers in immunology · 2022Review
- Crosstalk between ILC2s and Th2 CD4Journal of immunology research · 2022Review
- Role of Interleukin-1 family in bone metastasis of prostate cancer.Frontiers in oncology · 2022Review
- Single-cell transcriptomic landscape reveals tumor specific innate lymphoid cells associated with colorectal cancer progression.Cell reports. Medicine · 2021Article
- Review
- Serum free culture for the expansion and study of type 2 innate lymphoid cells.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
A new paradigm for understanding immune-surveillance and immune escape in cancer is described here. Metastatic carcinomas express reduced levels of IL-33 and diminished levels of antigen processing machinery (APM), compared to syngeneic primary tumours. Complementation of IL-33 expression in metastatic tumours upregulates APM expression and functionality of major histocompatibility complex (MHC)-molecules, resulting in reduced tumour growth rates and a lower frequency of circulating tumour cells. Parallel studies in humans demonstrate that low tumour expression of IL-33 is an immune biomarker associated with recurrent prostate and kidney renal clear cell carcinomas. Thus, IL-33 has a significant role in cancer immune-surveillance against primary tumours, which is lost during the metastatic transition that actuates immune escape in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.